Georgia Tomaras
Chief, Division of Surgical Sciences
A. Geller Distinguished Professor for Research in Immunology
Professor in Surgery
Professor in Integrative Immunobiology
Professor in Molecular Genetics and Microbiology
Affiliate, Duke Global Health Institute
Dr. Tomaras' overall research program is to understand the cellular and humoral immune response to HIV-1 infection and vaccination that are involved in protection from HIV-1. The research in the Tomaras laboratory centers around three main projects involving 1) antiviral CD8 T cell responses in HIV-1 infection and post vaccination, 2) mucosal and systemic antibody responses to infection and vaccination in both non-human primates and humans and 3) the ontogeny of neutralizing antibodies in HIV-1 infection. Her laboratory is also within the Duke Human Vaccine Institute.
Projects
-
Improved Global HIV-1 Incidence Assay
United States
Publications
-
Zeng YC, Young OJ, Xiong Q, Si L, Ku MW, Bernier SG, et al. DNA origami vaccine nanoparticles improve humoral and cellular immune responses to infectious diseases. Nat Biomed Eng. 2026 Mar 11;Kuzmina NA, Periasamy S, Kedarinath K, Hernandez K, Atyeo C, Dennison SM, et al. SARS-CoV-2 antibody-dependent enhancement of infection depends on antibody binding to both ACE2 and Fc receptors. JCI Insight. 2026 Feb 23;11(4).Brackett C, Zhang L, Do BTN, Baral S, Fisher LH, Hahn WO, et al. Early rise in nasal secretory IgA associated with shorter duration of SARS-CoV-2 virus shedding in an acute infection cohort. Front Immunol. 2026;17:1722585.Jamieson PJ, Shen X, Abu-Shmais AA, Wasdin PT, Janowska K, Edwards RJ, et al. Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity. J Virol. 2025 Dec 23;99(12):e0125625.
See more publications at Scholars@Duke